| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab. |
| Assessment Process | |
| Rapid review commissioned | 03/08/2016 |
| Rapid review completed | 24/08/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 31/08/2016 |
| Pre-submission consultation with Applicant | 10/10/2016 |
| Full submission received from Applicant | 21/07/2017 |
| Preliminary review sent to Applicant | 23/10/2017 |
| NCPE assessment re-commenced | 06/03/2018 |
| Factual accuracy sent to Applicant | 17/05/2018 |
| NCPE assessment re-commenced | 25/05/2018 |
| NCPE assessment completed | 28/05/2018 |
| NCPE assessment outcome | The NCPE recommends that pembrolizumab (Keytruda) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Reimbursement application withdrawn (November 2018)
